Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Visa to Move European Headquarters to London’s Canary Wharf 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Moderna’s mRNA patent for COVID has been declared invalid amid its dispute with rival BioNTech. The European Patent Office reportedly nullified one of the patents involved in a lawsuit and this decision is a defeat for the Cambridge, Massachusetts-based pharmaceutical and biotech firm.
BioNTech SE revealed on Tuesday, Nov. 21, that the European Patent Office announced that the mRNA patent that Moderna was appealing to in a litigation is not valid. This was in connection to the case filed by the latter, claiming that BioNTech and Pfizer violated a patent it is using, as per Reuters.
"We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," BioNTech said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted."
Moderna Loses COVID Vaccine Patent in Europe
Many manufacturers of COVID-19 vaccines have been fighting over patents. Moderna and BioNTech are two of the firms that have been engaged in heated court litigations for a long time. Pfizer, BioNTech’s partner is also involved and in the latest development, it appears that Moderna lost in its fight for mRNA’s patent in Europe after the EPO ruled it invalid.
Fierce Pharma reported that the patent owned by Moderna was canceled and this is the one that protects “respiratory virus vaccines.” Aside from Pfizer and BioNTech, France’s Sanofi S.A. is another pharmaceutical company that is opposing the patent that Moderna is trying to claim it owns the copyright to.
Patent Dispute Between Moderna and BioNTech
The dispute is mainly about two of Moderna’s patents namely: EP 3 590 949 B1 and EP 3 718 565 B1. The first one protects “ribonucleic acids containing n1-methyl-pseudouracils and uses thereof” while the second type protects “respiratory virus vaccines.”
Juve Patent mentioned that Moderna thinks Pfizer and BioNTech copied some features of these patented technologies that have become essential to the success of mRNA COVID-19 vaccines. However, on Nov. 21, the European Patent Office Opposition Division revoked one of the patents owned by Moderna, and in response, BioNTech said it welcomed the EPO’s decision.
On the other hand, Moderna said it will appeal this decision as it completely disagrees with it. The company added it believes the validity of its patent is still strong.
Photo by: Ian Hutchinson/Unsplash
